GLP1R and type 2 diabetes mellitus: Preclinical studies and clinical trials involving the use of GLP-1 receptor agonists have shown salutary cardiovascular effects and improved cardiovascular outcomes in T2DM (Love et al., 2020) but the precise impact of GLP-1 receptor agonists and SGLT2i on skeletal and myocardial capillary density and function remain unclear.